Furthermore, serum Gal-3 levels were significantly elevated in human PAH patients.[15, 16] These results support previous observations showing that Gal-3 blockade may be protective against hypertrophy and remodeling, and strengthen the hypothesis that Gal-3 targeted therapies may be useful in the treatment of pulmonary arterial hypertension. The gene discussed is LGALS3; the disease is pulmonary arterial hypertension.